### ORIGINAL ARTICLE



# Impact of postoperative complications after primary tumor resection on survival in patients with incurable stage IV colorectal cancer: A multicenter retrospective cohort study

Yusuke Fujita<sup>1</sup> | Koya Hida<sup>1</sup> | Nobuaki Hoshino<sup>1</sup> | Yoshiharu Sakai<sup>2</sup> | Tsuyoshi Konishi<sup>3</sup> | Akiyoshi Kanazawa<sup>4</sup> | Michitoshi Goto<sup>5</sup> | Shuji Saito<sup>6</sup> | Tadashi Suda<sup>7</sup> | Masahiko Watanabe<sup>8</sup> | Japan Society of Laparoscopic Colorectal Surgery

<sup>1</sup>Department of Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan

<sup>2</sup>Department of Surgery, Osaka Red Cross Hospital, Osaka, Japan

<sup>3</sup>Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

<sup>4</sup>Department of Surgery, Shimane Prefectural Central Hospital, Shimane, Japan

<sup>5</sup>Department of Coloproctological Surgery, Juntendo University Faculty of Medicine, Tokyo, Japan

<sup>6</sup>Division of Surgery, Gastrointestinal Center, Yokohama Shin-Midori General Hospital, Yokohama, Japan

<sup>7</sup>Suda Medical Clinic, Kawasaki, Japan

<sup>8</sup>Department of Surgery, Kitasato University School of Medicine, Kanagawa, Japan

#### Correspondence

Koya Hida, Department of Surgery, Kyoto University Graduate School of Medicine, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan. Email: hidakoya@kuhp.kyoto-u.ac.jp

**Funding information** Mitsubishi Foundation, Grant/Award Number: 30327

### Abstract

**Aims:** Primary tumor resection for patients with incurable stage IV colorectal cancer can prevent tumor-related complications but may cause postoperative complications. Postoperative complications delay the administration of chemotherapy and can lead to the spread of malignancy. However, the impact of postoperative complications after primary tumor resection on survival in patients with incurable stage IV colorectal cancer remains unclear. Therefore, this study aimed to investigate how postoperative complications after primary tumor resection affect survival in this patient group.

**Methods:** We reviewed data on 966 patients with stage IV colorectal cancer who underwent palliative primary tumor resection between January 2006 and December 2007. We examined the association between major complications (National Cancer Institute Common Terminology Criteria for Adverse Events v3.0 grade 3 or more) and overall survival using Cox proportional hazard model and explored risk factors associated with major complications using multivariable logistic regression analysis. **Results:** Ninety-three patients (9.6%) had major complications. The 2-year overall survival rate was 32.7% in the group with major complications and 50.3% in the group with no major complications. Patients with major complications had a significantly poorer prognosis than those without major complications (hazard ratio: 1.62; 95% confidence interval: 1.21-2.18; P < .01). Male, rectal tumor, and open surgery were identified to be risk factors for major complications.

**Conclusions:** Postoperative complications after primary tumor resection was associated with decreased long-term survival in patients with incurable stage IV colorectal cancer.

#### KEYWORDS

colorectal neoplasms, complication, primary tumor resection, stage IV, survival

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2021 The Authors. Annals of Gastroenterological Surgery published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Gastroenterology.

### 1 | INTRODUCTION

Colorectal cancer is the fourth most commonly diagnosed cancer and the second leading cause of cancer deaths worldwide.<sup>1</sup> Approximately 20% of all patients with colorectal cancer are diagnosed with stage IV cancer, and approximately 80% of those patients cannot undergo curative resection of the distant metastasis.<sup>2,3</sup>

The effectiveness of palliative primary tumor resection (PTR) for incurable stage IV patients is still controversial.<sup>4-6</sup> PTR could prevent tumor-related complications, such as intestinal obstruction, perforation, bleeding, or fistula.<sup>7-9</sup> Conversely, PTR may cause postoperative complications that requires time for the patients to recover from, which subsequently delays the administration of systemic chemotherapy and these delays can lead to the systemic spread of malignancy.<sup>10-12</sup>

Postoperative complications can worsen the long-term survival as well as short-term outcomes. Previous studies reported that postoperative complications decrease survival after curative surgery; however, only a few reports have focused on PTR for patients with incurable stage IV colorectal cancer.<sup>13-15</sup>

This study aimed to investigate the impact of postoperative complications after PTR on survival in patients with incurable stage IV colorectal cancer.

### 2 | METHODS

#### 2.1 | Study design and setting

This is a retrospective cohort study using data from the Japan Society of Laparoscopic Colorectal Surgery (JSLCS). The JSLCS retrospectively collected data on patients with stage IV colorectal cancer who underwent primary tumor resection at 41 participating hospitals between January 2006 and December 2007. This database did not include patients who underwent resection of metastasis with curative intent, irrespective of whether this was simultaneous or two-stage. All surgeons were experienced in laparotomy, and most have performed over 100 laparoscopic surgeries. Consecutive patient demographics and clinicopathological data, including patient characteristics, surgical findings, perioperative treatment, tumor stage, and survival, were collected retrospectively. The protocol for this research project has been approved by a suitably constituted Ethics Committee of Kyoto University (E631) and it conforms to the provisions of the Declaration of Helsinki.

#### 2.2 | Eligibility

Patients with stage IV disease were included in this study. From them, we excluded patients with postoperative 30-day or in-hospital death.

### 2.3 | Postoperative complications

Postoperative complications were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events v3.0 (CTCAE).<sup>16</sup> Major complications were defined as CTCAE grade 3 or 4. No major complications were defined as no complications or CTCAE grade 1 or 2. Surgical site infections and remote site infections were defined as infectious complications and any other complications were defined as non-infectious complications.<sup>17</sup>

#### 2.4 | Statistical analysis

Continuous variables were compared using the Mann-Whitney *U* test. Categorical valuables were compared using the Fisher's exact test.

Overall survival (OS) was defined as the time between the date of primary tumor resection and the date of death. Survival curves were created by Kaplan-Meier estimates, and they were compared by the log-rank test. Multivariable cox regression models were used to examine the association between major complications and OS, adjusting for all variables. Subgroup analyses were performed to explore the differences in impact of major complications on OS according to age, American Society of Anesthesiologists - Physical Status (ASA-PS), and the number of organs with residual tumor.

Multivariable logistic regression models were performed to explore factors associated with major complications. Of all the variables assessed, other than postoperative treatments, we selected variables that had a *P* value of <.1 in the univariable analysis or clinically relevant factors such as age, ASA-PS, emergency operation, tumor depth, and lymph node metastasis.

All *P* values were two-sided, and *P* values <.05 were considered statistically significant. All statistical analyses were performed using JMP Statistical Software Version 14 (SAS-Institute Inc, Cary, NC, USA).

### 3 | RESULTS

### 3.1 | Patient characteristics

Of 972 patients with stage IV disease, 966 patients were included after excluding those with postoperative death. Patient characteristics are shown in Table 1. Among them, 93 patients (9.6%) had major complications. The proportion of males, rectal tumor, open surgery, operative time  $\geq$ 240 minutes, and bleeding of  $\geq$ 100 mL tended to be higher in the major complications group.

Introduction of postoperative chemotherapy was delayed in patients with major complications compared to those with no major complications (44 vs 31 days, P < .01). Regarding the duration of the delay by each major complication, anastomotic leak was 48 days (interquartile range [IQR], 41-86), ileus/obstruction was 42 days (IQR, 27-63), wound infection was 36 days (IQR 25-61), lung infection was 36 days (IQR, 30-48), and intra-abdominal infection was 35 days (IQR 18-53).

### TABLE 1 Patient characteristics

Complication <sup>a</sup> Grade ± 2         Grade ± 3           Category          n         n         (%)           Total         966         873         (%)           Category          (%)           Grade ± 2         Grade ± 3           Grade 5 2         (%)           Category         n         (%)           Grade ± 3         (%)           Grade 5 2         (%)           - 400         633         (%)           Advalues         Grade ± 3           Male         411         S7         (%)           State         U           Advalues         Grade ± 3           Male         442         (%)           Advalues         7         (%)           Advalues         7         (%)           Advalope			
Category         n         (%)         n         (%)           Total         966         873         (90.4)         93         (9.6)           Clinical findings         Age (years)         -	Complication <sup>a</sup>	Comp	
Total         966         873         (90.4)         93         (9.6)           Clinical findings         Age (years)	$Grade \le 2 \qquad \qquad Grade \ge 3$	Grade	Factor
Clinical findings         Age (years)       70       639       582       (91.1)       57       (8.9) $<$ 70       639       582       (91.1)       57       (8.9)       36       (11.0)         Sex	n (%) n (%)	n	Category n
Age (years)<70	873 (90.4) 93 (9.6)	873	Total 966
$<70$ $639$ $582$ $(91,1)$ $57$ $(8,9)$ $≥70$ $327$ $291$ $(89,0)$ $36$ $(11,0)$ Sex $(88,0)$ $66$ $(12,0)$ Male $548$ $482$ $(88,0)$ $66$ $(12,0)$ Female $417$ $390$ $(93,5)$ $27$ $(6,5)$ Body mass index (kg/m²) $(90,4)$ $75$ $(9,6)$ $<225$ $783$ $708$ $(90,4)$ $75$ $(9,6)$ $255$ $171$ $156$ $(91,2)$ $15$ $(88)$ ASA-PS $(9,4)$ $(12,5)$ Emergency operation $(9,3)$ $(9,3)$ $(9,3)$ $ 907$ $823$ $(90,7)$ $84$ $(9,3)$ $+$ $59$ $50$ $(84,7)$ $9$ $(5,3)$ Previous laparotomy $(90,7)$ $66$ $(9,3)$ $+$ $233$ $212$ $(91,0)$ $21$ $(90,0)$ Preoperative chemotherapy $(90,4)$ $92$ $(9,6)$ $+$ $58$ $53$ $(91,4)$ $5$ $(86,6)$ Preoperative radiotherapy $99$ $90,00$ $1$ $+$ $10$ $9$ $(90,0)$ $1$ $(5,6)$ $e^{5}$ $189$ $178$ $(94,2)$ $11$ $(5,8)$ $25$ $763$ $684$ $89,6)$ $79$ $(10,4)$			Clinical findings
z70 $327$ $291$ $(89.0)$ $36$ $(11.0)$ Sex			Age (years)
Sex         Male         548         482         (88.0)         66         (12.0)           Female         417         390         (93.5)         27         (6.5)           Body mass index (kg/m <sup>2</sup> )         -         -         (6.6)         225         783         708         (90.4)         75         (9.6) $\sim 25$ 783         708         (90.4)         75         (9.6) $\sim 25$ 171         156         (91.2)         15         (8.8)           ASA-PS         -         -         -         -         (9.0)         82         (9.4)           II-IV         868         786         (90.5)         11         (12.5)           Emergency operation         -         -         907         823         (90.7)         84         (9.3)           +         59         50         (84.7)         9         (15.3)           Previous laparotomy         -         -         908         820         (90.7)         86         (9.0)           +         233         212         (91.0)         21         (9.0)           +         58         53         (90.4)         58         (8.	582 (91.1) 57 (8.9)	582	<70 639
Male548482(88.0)66(12.0)Female417390(93.5)27(6.5)Body mass index (kg/m²)<25783708(90.4)75(9.6) $\geq 25$ 171156(91.2)15(8.8)ASA-PSI-II868786(90.6)82(9.4)II-IV8877(87.5)11(12.5)Emergency operation-907823(90.7)84(9.3)+5950(84.7)9(15.3)Previous laparotomy-713647(90.7)66(9.3)+233212(90.3)88(9.7)+5853(91.4)5(8.6)Preoperative chemotherapy-956864(90.4)92(9.6)+109(90.0)1(10.0)CEA (ng/mL)<5189178(94.2)11(5.8) $\geq 5$ 763684(89.6)79(10.4)	291 (89.0) 36 (11.0)	291	≥70 327
Female417390(93.5)27(6.5)Body mass index (kg/m <sup>3</sup> )783708(90.4)75(9.6) $\geq 25$ 171156(91.2)15(8.8)ASA-PS11(12.5)I-II868786(90.6)82(9.4)III-IV8877(87.5)11(12.5)Emergency operation(9.3)4-907823(90.7)84(9.3)+5950(84.7)9(15.3)Previous laparotomy(90.3)84(9.3)+233212(91.0)21(9.0)Preoperative chemotherapy(8.6)(9.7)+5853(91.4)5(8.6)Preoperative radiotherapy(9.0)1(10.0)CEA (ng/mL)9(90.0)1(10.0)CEA (ng/mL) </td <td></td> <td></td> <td>Sex</td>			Sex
Body mass index (kg/m²) $< 25$ 783708(90.4)75(9.6) $> 25$ 171156(91.2)15(8.8)ASA-P5(9.4)(1.1)111868786(90.6)82(9.4)11-1V8877(87.5)11(12.5)Emergency operation(9.3)(9.7)-907823(90.7)84(9.3)+5950(84.7)9(15.3)Previous laparotomy(9.0)(9.0)-713647(90.7)66(9.3)+233212(91.0)21(9.0)Preoperative chemotherapy(86.4)(9.4)-908820(90.3)88(9.7)+5853(91.4)5(86.6)Preoperative radiotherapy(10.0)CEA (ng/mL)9(90.0)1(10.0)CEA (ng/mL)(94.2)11(5.8) $< 5$ 189178(94.2)11(5.8) $< 5$ 763684(89.6)79(10.4)	482 (88.0) 66 (12.0)	482	Male 548
< 25783708(90.4)75(9.6) $> 25$ 171156(91.2)15(8.8)ASA-PS $ I $ 868786(90.6)82(9.4) $ I  IV$ 8877(87.5)11(12.5)Emergency operation $-$ 907823(90.7)84(9.3) $+$ 5950(8.7)94(9.3) $+$ 233212(91.0)21(9.3) $+$ 233212(91.0)21(9.3) $+$ 5853(91.4)5(8.6)Preoperative chemotherapy $-$ 956864(90.4)92(9.6) $+$ 109(90.0)1(10.0)CEA (ng/mL) $< 5$ 189178(94.2)11(5.8) $< 5$ 763684(89.6)79(10.4)	390 (93.5) 27 (6.5)	390	Female 417
			Body mass index (kg/m²)
ASA-PS         I-II         868         786         (90.6)         82         (9.4)           III-IV         88         77         (87.5)         11         (12.5)           Emergency operation         -         907         823         (90.7)         84         (9.3)           +         59         50         (84.7)         9         (15.3)           Previous laparotomy         -         713         647         (90.7)         66         (9.3)           +         233         212         (91.0)         21         (90.7)           Preoperative chemotherapy         -         58         53         (91.4)         5         (8.6)           Preoperative radiotherapy         -         58         53         (91.4)         5         (8.6)           Preoperative radiotherapy         -         908         820         (90.3)         88         (97.7)           -         908         820         (90.3)         88         (97.7)         (8.6)           Preoperative radiotherapy         -         58         53         (91.4)         5         (8.6)           -         956         864         (90.0)         1         (10.0) <td>708 (90.4) 75 (9.6)</td> <td>708</td> <td>&lt;25 783</td>	708 (90.4) 75 (9.6)	708	<25 783
I-II         868         786         (90.6)         82         (9.4)           III-IV         88         77         (87.5)         11         (12.5)           Emergency operation         -         907         823         (90.7)         84         (9.3)           -         907         823         (90.7)         84         (9.3)           +         59         50         (84.7)         9         (15.3)           Previous laparotomy         -         -         (9.3)         (9.7)         66         (9.3)           +         233         212         (91.0)         21         (90.7)           Preoperative chemotherapy         -         -         (90.7)         66         (9.3)           +         233         212         (91.0)         21         (90.0)           Preoperative chemotherapy         -         -         (90.8)         (90.4)         5         (8.6)           Preoperative radiotherapy         -         -         956         864         (90.4)         92         (9.6)           +         10         9         (90.0)         1         (10.0)           CEA (ng/mL)         -         189	156 (91.2) 15 (8.8)	156	≥25 171
III-IV         88         77         (87.5)         11         (12.5)           Emergency operation         -         907         823         (90.7)         84         (9.3)           -         907         50         (84.7)         9         (15.3)           Previous laparotomy         -         713         647         (90.7)         66         (9.3)           +         233         212         (91.0)         21         (90.7)           Preoperative chemotherapy         -         713         647         (90.7)         66         (9.3)           +         233         212         (91.0)         21         (90.7)           Preoperative chemotherapy         -         908         820         (90.3)         88         (97.7)           +         58         53         (91.4)         5         (8.6)           Preoperative radiotherapy         -         956         864         (90.4)         92         (9.6)           +         10         9         (90.0)         1         (10.0)         (10.4)           CEA (ng/mL)         -         -         5         11         (5.8)         5         5         53			
Emergency operation-907823(90.7)84(9.3)+5950(84.7)9(15.3)Previous laparotomy-713647(90.7)66(9.3)+233212(91.0)21(90.0)Preoperative chemotherapy $-$ 908820(90.3)88(9.7)+5853(91.4)5(8.6)Preoperative radiotherapy $-$ 956864(90.4)92(9.6)+109(90.0)1(10.0)CEA (ng/mL) $-$ 189178(94.2)11(5.8) $\geq 5$ 763684(89.6)79(10.4)			
$\begin{array}{c c c c c c c } - & 907 & 823 & (90.7) & 84 & (9.3) \\ + & 59 & 50 & (84.7) & 9 & (15.3) \\ \hline Previous laparotomy & & & & & & & & & & & & & & & & & & &$	77 (87.5) 11 (12.5)	77	III-IV 88
$+$ 5950(84.7)9(15.3)Previous laparotomy $-$ 713647(90.7)66(9.3) $+$ 233212(91.0)21(90.0)Preoperative chemotherapy $-$ 908820(90.3)88(9.7) $+$ 5853(91.4)5(8.6)Preoperative radiotherapy $-$ 956864(90.4)92(9.6) $+$ 109(90.0)1(10.0)CEA (ng/mL) $<5$ 189178(94.2)11(5.8) $\geq 5$ 763684(89.6)79(10.4)			
Previous laparotomy         647         (90.7)         66         (9.3)         (9.4)         (9.4)         (9.4)         (9.4)         (9.4)         (9.4)         (9.4)         (9.4)         (9.4)         (9.4)         (9.4)         (9.4)         (9.4)         (9.4)			
$-$ 713647(90.7)66(9.3) $+$ 233212(91.0)21(9.0)Preoperative chemotherapy $-$ 908820(90.3)88(9.7) $+$ 5853(91.4)5(8.6)Preoperative radiotherapy $-$ 956864(90.4)92(9.6) $+$ 109(90.0)1(10.0)CEEA (ng/mL) $<5$ 189178(94.2)11(5.8) $\geq 5$ 763684(89.6)79(10.4)	50 (84.7) 9 (15.3)	50	
$+$ 233212(91.0)21(9.0)Preoperative chemotherapy $-$ 908820(90.3)88(9.7) $+$ 5853(91.4)5(8.6)Preoperative radiotherapy $-$ 956864(90.4)92(9.6) $+$ 109(90.0)1(10.0)CEA (ng/mL) $<5$ 189178(94.2)11(5.8) $\geq5$ 763684(89.6)79(10.4)			
Preoperative chemotherapy       -       908       820       (90.3)       88       (9.7)         +       58       53       (91.4)       5       (8.6)         Preoperative radiotherapy       -       -       956       864       (90.4)       92       (9.6)         +       10       9       (90.0)       1       (10.0)         CEA (ng/mL)       -       -       -       53       (94.2)       11       (5.8)         ≥5       763       684       (89.6)       79       (10.4)       10       10			
$-$ 908820(90.3)88(9.7) $+$ 5853(91.4)5(8.6)Preoperative radiotherapy $-$ 956864(90.4)92(9.6) $+$ 109(90.0)1(10.0)CEA (ng/mL) $<5$ 189178(94.2)11(5.8) $\geq5$ 763684(89.6)79(10.4)	212 (91.0) 21 (9.0)	212	
+         58         53         (91.4)         5         (8.6)           Preoperative radiotherapy            (9.6)			
Preoperative radiotherapy         -         956         864         (90.4)         92         (9.6)           +         10         9         (90.0)         1         (10.0)           CEA (ng/mL)           178         (94.2)         11         (5.8)           ≥5         763         684         (89.6)         79         (10.4)			
-         956         864         (90.4)         92         (9.6)           +         10         9         (90.0)         1         (10.0)           CEA (ng/mL)           178         (94.2)         11         (5.8)           ≥5         763         684         (89.6)         79         (10.4)	53 (91.4) 5 (8.6)	53	
+         10         9         (90.0)         1         (10.0)           CEA (ng/mL)         -			
CEA (ng/mL)         178       (94.2)       11       (5.8)         ≥5       763       684       (89.6)       79       (10.4)			
<5 189 178 (94.2) 11 (5.8) ≥5 763 684 (89.6) 79 (10.4)	9 (90.0) 1 (10.0)	9	
≥5 763 684 (89.6) 79 (10.4)			
Tumor location	684 (89.6) 79 (10.4)	684	
Right colon         323         299         (92.6)         24         (7.4)			
Left colon 452 412 (91.2) 40 (8.8)			
Rectum 177 148 (83.6) 29 (16.4)	148 (83.6) 29 (16.4)	148	
Perioperative intestinal stenosis		100	
- 474 429 (90.5) 45 (9.5)			
+ 462 420 (90.9) 42 (9.1)	420 (90.9) 42 (9.1)	420	
Symptom(s) relating to primary tumor <sup>b</sup>			
Asymptomatic         432         393         (91.0)         39         (9.0)			
Symptomatic         505         456         (90.3)         49         (9.7)	456 (90.3) 49 (9.7)	456	
Surgical findings			
Surgical approach		15.	
Open 737 654 (88.7) 83 (11.3)	054 (88.7) 83 (11.3)	654	Open /3/

FUJITA ET AL.

(Continues)

### TABLE 1 (Continued)

		Complicat	ion <sup>a</sup>		
Factor		Grade ≤ 2		Grade ≥ 3	
Category	n	n	(%)	n	(%)
Lap	229	219	(95.6)	10	(4.4)
Additional operation					
-	770	700	(90.9)	70	(9.1)
+	196	173	(88.3)	23	(11.7)
Operative time (min)					
<240	696	638	(91.7)	58	(8.3)
≥240	267	232	(86.9)	35	(13.1)
Bleeding (mL)					
<100	387	362	(93.5)	25	(6.5)
≥100	570	502	(88.1)	68	(11.9)
Intraoperative complications					
-	956	863	(90.3)	93	(9.7)
+	10	10	(100.0)	0	(0.0)
Tumor development					
Tumor depth					
≤T3	525	479	(91.2)	46	(8.8)
T4	441	394	(89.3)	47	(10.7)
Lymph node metastasis					
-	157	146	(93.0)	11	(7.0)
+	787	706	(89.7)	81	(10.3)
Hepatic metastasis					
-	269	245	(91.1)	24	(8.9)
+	691	622	(90.0)	69	(10.0)
Peritoneal metastasis					
-	683	622	(91.1)	61	(8.9)
+	277	246	(88.8)	31	(11.2)
Other distant metastasis					
-	548	492	(89.8)	56	(10.2)
+	409	373	(91.2)	36	(8.8)
Number of organs with residual	tumors				
1	625	570	(91.2)	55	(8.8)
≥2	341	303	(88.9)	38	(11.1)
Postoperative treatment					
Postoperative chemotherapy					
-	174	146	(83.9)	28	(16.1)
+	792	727	(91.8)	65	(8.2)
Days to start chemotherapy <sup>c</sup>		31	(20-45)	44	(33-60)
Other postoperative therapies					
-	840	753	(89.6)	87	(10.4)
+	126	120	(95.2)	6	(4.8)

Abbreviations: ASA-PS, American Society of Anesthesiologists - Physical Status; CEA, carcinoembryonic antigen.

<sup>a</sup>Postoperative complications were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events v3.0.

<sup>b</sup>Symptom(s) relating to primary tumor are defined as symptoms indicating anemia (hemoglobin, <9 mg/L) and intestinal stricture, signifying that the colon fiberscope could not be inserted on the oral side due to colorectal tumor.

<sup>c</sup>Median (interquartile range).

### 3.2 | Details of postoperative complications

The characteristics of postoperative complications are described in Table 2. There was a total of 246 complications, including 92 grade 3 complications and 11 grade 4 complications. Anastomotic leak, ileus/obstruction, and wound infection were the most common complications. Infectious major complications were found in 53 patients and non-infectious major complications were found in 46 patients. Multiple complications were found in 21 patients.

### 3.3 | Factors associated with major complications

In the logistic regression model, male, rectal tumor, and open surgery were significantly associated with major complications (Table 3).

### 3.4 | Survival analysis

The OS curves of patients stratified by major or no major postoperative complications are shown in Figure 1. The 2-year OS rate was

CTCAE grade	Grade 1-2	Grade 3	Grade 4	Total	(%)	
Anastomotic leak	13	21	2	36	(3.7)	
Ileus/Obstruction	36	32	2	70	(7.2)	
Wound infection	59	9	1	69	(7.1)	
Intra-abdominal infection	11	6	1	18	(1.9)	
Urinary dysfunction	6	3	0	9	(0.9)	
Bleeding	1	2	0	3	(0.3)	
Stroke	0	0	3	3	(0.3)	
PE/DVT	0	2	0	2	(0.2)	
Lung infection	1	6	1	8	(0.8)	
Others	16	11	1	28	(2.9)	
Total	143	92	11	246		
Multiple complications: 21 cases						


Abbreviations: CTCAE, National Cancer Institute Common Terminology Criteria for Adverse Events v3.0; DVT, deep venous thrombosis; PE, pulmonary embolism.

Variables	Category			Adjusted OR	95% CI	P value
Clinical findings						
Age (years)	≥70	/	<70	1.36	[0.86-2.16]	.19
Sex	Male	/	Female	1.76	[1.09-2.85]	.02
ASA-PS	III-IV	/	1-11	1.16	[0.55-2.45]	.70
Emergency operation	+	/	-	1.53	[0.65-3.57]	.33
Tumor location	Rectum	/	Colon	1.92	[1.14-3.24]	.01
Surgical findings						
Surgical approach	Open	/	Lap	2.55	[1.24-5.23]	.01
Operative time (min)	≥240	/	<240	1.53	[0.91-2.56]	.11
Bleeding (mL)	≥100	/	<100	1.17	[0.68-2.01]	.57
Tumor development						
Tumor depth	T4	/	≤T3	1.17	[0.75-1.84]	.48
Lymph node metastasis	+	/	-	1.44	[0.73-2.83]	.29

Abbreviations: ASA-PS, American Society of Anesthesiologists - Physical Status; CI, confidence interval; OR, odds ratio.

### TABLE 2 Postoperative complications

TABLE 3	Factors	associated	with	major
complicatior	IS			



**FIGURE 1** Overall survival of patients stratified by the presence or absence of major postoperative complications

50.3% in the group with no major complications and 32.7% in the group with major complications. OS was significantly lower in the group of major complications (P < .01). The OS curves of patients based on type of complication (infectious or non-infectious) are shown in Figure 2. Subgroup analyses according to age, ASA-PS, and the number of organs with residual tumor are shown in Figure 3.

In the Cox proportional hazards model, major complications were significantly associated with poor OS (hazard ratio: 1.62; 95% confidence interval: 1.21-2.18; P < .01), after adjusting for all factors of patient characteristics (Table 4).

### 4 | DISCUSSION

In this study, we showed that patients with stage IV colorectal cancer with major postoperative complications after PTR had a poor prognosis. In addition, we identified that male sex, rectal tumor, and open surgery were significantly associated with major complications.

Several mechanisms have been proposed to explain the negative impact of postoperative complications on oncologic outcomes. Postoperative complications lead to the omission or delay in administering postoperative chemotherapy.<sup>15,18,19</sup> In this study, patients in the major complications group had an increased delay for the start of postoperative chemotherapy compared to patients with no major complications. In addition, postoperative complications cause inhibition of the adaptive immune response secondary to tissue damage, anesthesia, blood transfusion, and, in particular, infectious complications.<sup>13,20</sup> The negative effect of complications was reportedly greater in more advanced stages.<sup>21,22</sup> Several studies have reported on the impact of postoperative complications on long-term survival after colorectal cancer surgery, including curative surgery for patients with stages I-III diseases (hazard ratio: 1.24-1.36)<sup>13,21</sup> and curative hepatic resection for colorectal liver metastasis (hazard ratio: 1.41-1.52).<sup>23,24</sup> Our results for incurable colorectal cancer (hazard ratio: 1.62) corresponded to the previous studies.

This study attempted to explore the difference in the impact of postoperative complications on prognosis based on the type of complication. Previous studies have demonstrated that the infectiousness of complications worsened patients' prognoses.<sup>13,23</sup> On the other hand, the results of this study are consistent with those of a systematic review by McSorley et al,<sup>17</sup> which reported that the prognostic impact of infectious complications and that of non-infectious complications were similar. In addition, this study investigated the impact of major complications on OS stratified by age, ASA-PS, and the number of organs with residual tumors. The prognostic impact of major complications appeared similar in all the subgroups.

Many studies have reported on the risk factors for postoperative complications in patients undergoing curative surgery such as age, sex, ASA-PS, emergency operation, tumor location, surgical approach, and disease stage.<sup>13,19,25</sup> On the other hand, few studies have referred to incurable patients. Stillwell et al reported sex, advanced local disease, repeat operations, elevated urea levels, and emergency operations as risk factors for the complications in incurable surgery.<sup>26</sup> However, in that study, the colon and rectum were not distinguished, and laparoscopic surgery was not performed. In this study, male, rectal tumor, and open





FIGURE 2 Overall survival of patients based on type of complications: (A) Infectious complications; (B) Non-infectious complications



**FIGURE 3** Subgroup analyses on overall survival stratified by the presence or absence of major postoperative complications, according to age, American Society of Anesthesiologists - Physical Status (ASA-PS), and the number of organs with residual tumor: (A) Age < 70, (B) Age  $\geq$  70, (C) ASA-PS = I-II, (D) ASA-PS = III-IV, (E) Organs with residual tumors = 1, (F) Organs with residual tumors  $\geq$  2

surgery were factors associated with major complications. PTR is sometimes inevitable for patients with incurable colorectal cancer because of tumor-related symptoms, such as intestinal stenosis and bleeding.<sup>27</sup> Surgeons should consider such risk factors when performing PTR. Laparoscopic surgery would be a good option, as it reportedly has a lower complication rate and similar prognosis compared to open surgery in previous studies on curative surgery.<sup>25,28-30</sup>

#### TABLE 4 Association between major complications with overall survival

						Р
Variables	Category			Adjusted HR	95% CI	value
Postoperative complications <sup>a</sup>	Grade ≥ 3	/	Grade ≤ 2	1.62	[1.21-2.18]	<.01
Clinical findings						
Age (years)	≥70	/	<70	1.37	[1.12-1.67]	<.01
Sex	Male	/	Female	1.11	[0.92-1.34]	.27
Body mass index (kg/m²)	≥25	/	<25	0.87	[0.68-1.11]	.28
ASA-PS	III-IV	/	1-11	1.50	[1.10-2.01]	.01
Emergency operation	+	/	-	0.81	[0.53-1.19]	.29
Previous laparotomy	+	/	-	1.22	[0.99-1.51]	.06
Preoperative chemotherapy	+	/	-	1.29	[0.84-1.90]	.24
Preoperative radiotherapy	+	/	-	1.05	[0.38-2.48]	.91
CEA (ng/mL)	≥5	/	<5	1.33	[1.03-1.73]	.03
Tumor location Left colon	Left colon	/	Right colon	0.79	[0.64-0.98]	.04
Tumor location Rectum	Rectum	/	Right colon	0.99	[0.73-1.32]	.93
Preoperative intestinal stenosis	+	/	-	1.22	[1.01-1.48]	.03
Surgical findings						
Surgical approach	Open	/	Lap	0.97	[0.77-1.24]	.83
Additional operation	+	/	_	0.87	[0.68-1.10]	.24
Operative time (min)	≥240	/	<240	0.67	[0.52-0.86]	<.01
Bleeding (mL)	≥100	/	<100	0.95	[0.77-1.17]	.62
Intraoperative complications	+	/	-	1.60	[0.73-3.51]	.24
Tumor development						
Tumor depth	T4	/	≤T3	1.21	[1.00-1.46]	.05
Lymph node metastasis	+	/	-	1.66	[1.25-2.20]	<.01
Hepatic metastasis	+	/	-	1.89	[1.49-2.39]	<.01
Peritoneal metastasis	+	/	-	1.28	[1.02-1.60]	.03
Other distant metastasis	+	/	-	1.42	[1.18-1.72]	<.01
Postoperative treatment						
Postoperative chemotherapy	+	/	-	0.49	[0.39-0.63]	<.01
Other postoperative therapy	+	/	-	0.40	[0.29-0.56]	<.01

Abbreviations: ASA-PS, American Society of Anesthesiologists - Physical Status; CEA, carcinoembryonic antigen; CI, confidence interval; HR, hazard ratio.

<sup>a</sup>Postoperative complications were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events v3.0.

The strength of this study is that it is the first study to clarify the association between postoperative complications and survival following PTR for patients with incurable colorectal cancer. Additionally, we utilized a large cohort of patients with incurable stage IV colorectal cancer to adjust for as many confounders as possible. However, this study has some limitations. This is a retrospective cohort study, and thus there might be unmeasurable confounding factors that could influence the study results. In addition, we could not obtain information on patient comorbidities and details of postoperative therapies. Nevertheless, we believe that the results of our study provide important information for surgeons engaging the treatment of incurable colorectal cancer. In conclusion, the major postoperative complications after PTR worsened the prognosis of patients with incurable stage IV colorectal cancer.

#### DISCLOSURE

Funding: This study was supported by the Mitsubishi Foundation (30327).

Conflict of Interest: The authors declare that they have no conflict of interest.

### ORCID

Yusuke Fujita <sup>D</sup> https://orcid.org/0000-0002-4679-7065 Koya Hida <sup>D</sup> https://orcid.org/0000-0001-7210-7075

AGSurg Annals of Gastroenterological Surgery

## Nobuaki Hoshino Dhttps://orcid.org/0000-0002-7171-8971

#### REFERENCES

 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin. 2018;68(6):394–424.

-WILEY- AGSurg Annals of Gastroenterological Surgery

- Cook AD, Single R, McCahill LE. Surgical resection of primary tumors in patients who present with stage IV colorectal cancer: an analysis of surveillance, epidemiology, and end results data, 1988 to 2000. Ann Surg Oncol. 2005;12(8):637–45.
- Mella J, Datta SN, Biffin A, Radcliffe AG, Steele RJ, Stamatakis JD. Surgeons' follow-up practice after resection of colorectal cancer. Ann R Coll Surg Engl. 1997;79(3):206–9.
- Biondo S, Frago R, Kreisler E, Espin-Basany E. Impact of resection versus no resection of the primary tumor on survival in patients with colorectal cancer and synchronous unresectable metastases: protocol for a randomized multicenter study (CR4). Int J Colorectal Dis. 2017;32(7):1085–90.
- Kim CW, Baek JH, Choi GS, Yu CS, Kang SB, Park WC, et al. The role of primary tumor resection in colorectal cancer patients with asymptomatic, synchronous unresectable metastasis: study protocol for a randomized controlled trial. Trials. 2016;17:34.
- Moritani K, Kanemitsu Y, Shida D, Shitara K, Mizusawa J, Katayama H, et al. A randomized controlled trial comparing primary tumour resection plus chemotherapy with chemotherapy alone in incurable stage IV colorectal cancer: JCOG1007 (iPACS study). Jpn J Clin Oncol. 2020;50(1):89–93.
- Mäkelä J, Haukipuro K, Laitinen S, Kairaluoma MI. Palliative operations for colorectal cancer. Dis Colon Rectum. 1990;33(10):846–50.
- Kim MS, Chung M, Ahn JB, Kim CW, Cho MS, Shin SJ, et al. Clinical significance of primary tumor resection in colorectal cancer patients with synchronous unresectable metastasis. J Surg Oncol. 2014;110(2):214–21.
- Karoui M, Roudot-Thoraval F, Mesli F, Mitry E, Aparicio T, Des Guetz G, et al. Primary colectomy in patients with stage IV colon cancer and unresectable distant metastases improves overall survival: results of a multicentric study. Dis Colon Rectum. 2011;54(8):930-8.
- Poultsides GA, Servais EL, Saltz LB, Patil S, Kemeny NE, Guillem JG, et al. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol. 2009;27(20):3379–84.
- Benoist S, Pautrat K, Mitry E, Rougier P, Penna C, Nordlinger B. Treatment strategy for patients with colorectal cancer and synchronous irresectable liver metastases. Br J Surg. 2005;92(9):1155–60.
- Muratore A, Zorzi D, Bouzari H, Amisano M, Massucco P, Sperti E, et al. Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy? Ann Surg Oncol. 2007;14(2):766–70.
- Artinyan A, Orcutt ST, Anaya DA, Richardson P, Chen GJ, Berger DH. Infectious postoperative complications decrease long-term survival in patients undergoing curative surgery for colorectal cancer: a study of 12,075 patients. Ann Surg. 2015;261(3):497–505.
- Cienfuegos JA, Baixauli J, Beorlegui C, Ortega PM, Granero L, Zozaya G, et al. The impact of major postoperative complications on long-term outcomes following curative resection of colon cancer. Int J Surg (London, England). 2018;52:303–8.
- Odermatt M, Miskovic D, Flashman K, Khan J, Senapati A, O'Leary D, et al. Major postoperative complications following elective resection for colorectal cancer decrease long-term survival but not the time to recurrence. Colorectal Dis. 2015;17(2):141–9.
- Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Sem Radiation Oncol. 2003;13(3):176-81.

- McSorley ST, Horgan PG, McMillan DC. The impact of the type and severity of postoperative complications on long-term outcomes following surgery for colorectal cancer: a systematic review and meta-analysis. Critical Rev Oncol Hematol. 2016;97:168–77.
- Hendren S, Birkmeyer JD, Yin H, Banerjee M, Sonnenday C, Morris AM. Surgical complications are associated with omission of chemotherapy for stage III colorectal cancer. Dis Colon Rectum. 2010;53(12):1587–93.
- Law WL, Choi HK, Lee YM, Ho JW. The impact of postoperative complications on long-term outcomes following curative resection for colorectal cancer. Ann Surg Oncol. 2007;14(9):2559–66.
- Mörner ME, Edgren G, Martling A, Gunnarsson U, Egenvall M. Preoperative anaemia and perioperative red blood cell transfusion as prognostic factors for recurrence and mortality in colorectal cancer-a Swedish cohort study. Int J Colorectal Dis. 2017;32(2):223–32.
- 21. Richards CH, Platt JJ, Anderson JH, McKee RF, Horgan PG, McMillan DC. The impact of perioperative risk, tumor pathology and surgical complications on disease recurrence following potentially curative resection of colorectal cancer. Ann Surg. 2011;254(1):83–9.
- Al-Sukhni E, Attwood K, Gabriel EM, LeVea CM, Kanehira K, Nurkin SJ. Lymphovascular and perineural invasion are associated with poor prognostic features and outcomes in colorectal cancer: a retrospective cohort study. Int J Surg (London, England). 2017;37:42–9.
- Farid SG, Aldouri A, Morris-Stiff G, Khan AZ, Toogood GJ, Lodge JP, et al. Correlation between postoperative infective complications and long-term outcomes after hepatic resection for colorectal liver metastasis. Ann Surg. 2010;251(1):91–100.
- Yin Z, Huang X, Ma T, Jin H, Lin Y, Yu M, et al. Postoperative complications affect long-term survival outcomes following hepatic resection for colorectal liver metastasis. World J Surg. 2015;39(7):1818–27.
- Guillou PJ, Quirke P, Thorpe H, Walker J, Jayne DG, Smith AM, et al. Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial. Lancet (London, England). 2005;365(9472):1718–26.
- Stillwell AP, Buettner PG, Siu SK, Stitz RW, Stevenson AR, Ho YH. Predictors of postoperative mortality, morbidity, and long-term survival after palliative resection in patients with colorectal cancer. Dis Colon Rectum. 2011;54(5):535–44.
- Pedziwiatr M, Mizera M, Witowski J, Major P, Torbicz G, Gajewska N, et al. Primary tumor resection in stage IV unresectable colorectal cancer: what has changed? Medical Oncol (Northwood, London, England). 2017;34(12):188.
- Jayne DG, Guillou PJ, Thorpe H, Quirke P, Copeland J, Smith AM, et al. Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial Group. J Clin Oncol. 2007;25(21):3061–8.
- Hida K, Hasegawa S, Kinjo Y, Yoshimura K, Inomata M, Ito M, et al. Open versus laparoscopic resection of primary tumor for incurable stage IV colorectal cancer: a large multicenter consecutive patients cohort study. Ann Surg. 2012;255(5):929–34.
- Toda S, Kuroyanagi H. Laparoscopic surgery for rectal cancer: current status and future perspective. Asian J Endoscopic Surg. 2014;7(1):2–10.

How to cite this article: Fujita Y, Hida K, Hoshino N, et al. Impact of postoperative complications after primary tumor resection on survival in patients with incurable stage IV colorectal cancer: A multicenter retrospective cohort study. Ann Gastroenterol Surg. 2021;5:354–362. <u>https://doi.</u> org/10.1002/ags3.12433